QIAGEN Partners with Verogen to Offer Broadest Portfolio for Human Identification, Including Next Generation Sequencing Solut...
June 29 2021 - 4:05PM
Business Wire
- QIAGEN increases forensics market lead with solutions from
sample collection to identification
- Collaboration will provide customers workflow tools and support
for highest quality outcomes
- Verogen broadens reach of sequencing and analysis products for
forensic and human identity samples
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today
announced a commercialization partnership with San Diego-based
human identification specialist Verogen that will provide customers
of both companies with superior tools and comprehensive support for
human identification (HID) workflows in their laboratories.
The deal enables QIAGEN to offer Verogen’s preeminent HID
sequencing and analysis solutions that run on MiSeq FGx® sequencers
from Illumina, decisively expanding QIAGEN’s forensics leadership
that already covers sample collection and preparation, genetic
testing analysis and workflow automation. The agreement grants
QIAGEN the rights to distribute the Verogen portfolio globally –
including kits based on the proprietary Verogen ForenSeq® assay,
the Verogen MiSeq FGx® Sequencing System and the Universal Analysis
Software – and covers an expansion of the partnership through
future ForenSeq-based assays.
Verogen and QIAGEN will also cooperate to commercialize a menu
of forensically validated workflows for next-generation sequencing
(NGS) that combine Verogen’s library-prep products with QIAGEN’s
QIAseq products, automation solutions and expertise. QIAGEN will
market Verogen products globally alongside its portfolio of
forensics instruments, kits and services. Financial details of the
deal are not being disclosed.
“This combination brings together Verogen’s innovative NGS
workflows with QIAGEN’s leading portfolio of Sample to Insight
solutions, creating the most comprehensive product offering for
forensics applications,” said Thierry Bernard, Chief Executive
Officer at QIAGEN. “The partnership will drive the adoption of NGS
in human identification as it will enable our customers to gain
even better insights from their casework samples. This will
ultimately strengthen justice systems all over the world.”
“Our mission is to empower the human identification community
with innovative tools that can deliver an identification, not just
a DNA profile,” said Brett Williams, Chief Executive Officer at
Verogen. “This partnership with QIAGEN will make it easier for
laboratories to provide more impactful answers. By combining
Verogen’s industry-leading NGS-based product portfolio with
QIAGEN’s gold-standard extraction, assay and automation solutions,
we will accelerate adoption and use of NGS in forensics.”
NGS is used in many biotechnological fields, from cancer
research to rare-disease testing. In forensics, it opens completely
new opportunities for criminal casework, missing persons and
disaster-victim identification. While traditional STR-profiling
requires a suspect or a database hit to compare with a crime
sample, NGS provides additional intelligence options such as
estimation of externally visible characteristics like hair or eye
color, thereby elevating DNA testing from a passive forensic
support to a proactive investigational technique.
Experts expect the market for NGS in forensics to grow at a
double-digit rate annually because of its promising
applications.
This collaboration of market leaders addresses important hurdles
in areas like workflow integration, automation and vendor support
that have slowed adoption of NGS in forensics. The partnership
bolsters the workflow solutions offered by QIAGEN and Verogen by
offering forensic customers a new level of end-to-end support
across the globe, from sample collection to data interpretation and
analysis.
QIAGEN is a world leader in HID and forensic testing. It offers
a full range of forensic-grade chemistries and high-quality
instruments, such as the new EZ2 Connect Fx that address the
challenges of crime scene investigation and more. Covering every
step from sample to insight, QIAGEN has shaped the development of
forensic standards, supporting criminal justice and missing persons
identification. QIAGEN’s top-quality forensics products and
services are helping customers unlock vital molecular insights to
make improvements in life possible.
Find out more about QIAGEN’s human identification portfolio
here:
https://www.qiagen.com/us/applications/human-identity-and-forensics/
About Verogen
Verogen is a dedicated developer of DNA-based biometric human
identification products for analysis of forensic genomic samples.
Working closely with the forensic community, Verogen places
exceptional value on flexible, scalable solutions that deliver
reliable results. To learn more, visit www.verogen.com
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading
global provider of Sample to Insight solutions that enable
customers to gain valuable molecular insights from samples
containing the building blocks of life. Our sample technologies
isolate and process DNA, RNA and proteins from blood, tissue and
other materials. Assay technologies make these biomolecules visible
and ready for analysis. Bioinformatics software and knowledge bases
interpret data to report relevant, actionable insights. Automation
solutions tie these together in seamless and cost-effective
workflows. QIAGEN provides solutions to more than 500,000 customers
around the world in Molecular Diagnostics (human healthcare) and
Life Sciences (academia, pharma R&D and industrial
applications, primarily forensics). As of March 31, 2021, QIAGEN
employed approximately 5,700 people in over 35 locations worldwide.
Further information can be found at http://www.qiagen.com
Forward-Looking Statement
Certain statements contained in this press release may be
considered forward-looking statements within the meaning of Section
27A of the U.S. Securities Act of 1933, as amended, and Section 21E
of the U.S. Securities Exchange Act of 1934, as amended. To the
extent that any of the statements contained herein relating to
QIAGEN's products, including those products used in the response to
the COVID-19 pandemic, timing for launch and development, marketing
and/or regulatory approvals, financial and operational outlook,
growth and expansion, collaborations markets, strategy or operating
results, including without limitation its expected adjusted net
sales and adjusted diluted earnings results, are forward-looking,
such statements are based on current expectations and assumptions
that involve a number of uncertainties and risks. Such
uncertainties and risks include, but are not limited to, risks
associated with management of growth and international operations
(including the effects of currency fluctuations, regulatory
processes and dependence on logistics), variability of operating
results and allocations between customer classes, the commercial
development of markets for our products to customers in academia,
pharma, applied testing and molecular diagnostics; changing
relationships with customers, suppliers and strategic partners;
competition; rapid or unexpected changes in technologies;
fluctuations in demand for QIAGEN's products (including
fluctuations due to general economic conditions, the level and
timing of customers' funding, budgets and other factors); our
ability to obtain regulatory approval of our products; difficulties
in successfully adapting QIAGEN's products to integrated solutions
and producing such products; the ability of QIAGEN to identify and
develop new products and to differentiate and protect our products
from competitors' products; market acceptance of QIAGEN's new
products and the integration of acquired technologies and
businesses; actions of governments, global or regional economic
developments, weather or transportation delays, natural disasters,
political or public health crises, including the breadth and
duration of the COVID-19 pandemic and its impact on the demand for
our products and other aspects of our business, or other force
majeure events; as well as the possibility that expected benefits
related to recent or pending acquisitions may not materialize as
expected; and the other factors discussed under the heading “Risk
Factors” contained in Item 3 of our most recent Annual Report on
Form 20-F. For further information, please refer to the discussions
in reports that QIAGEN has filed with, or furnished to, the U.S.
Securities and Exchange Commission.
Source: QIAGEN N.V. Category: Corporate
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210629006025/en/
QIAGEN Investor Relations John Gilardi +49 2103 29
11711 Phoebe Loh +49 2103 29 11457 e-mail: ir@QIAGEN.com Public
Relations Thomas Theuringer +49 2103 29 11826 Robert Reitze +49
2103 29 11676 e-mail: pr@QIAGEN.com Verogen Kim Mohr Insight
Communications 949-322-3733 insight.kmohr@gmail.com
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024